AzTrials
AzTrials

AllergicPhase 1GammaphilNCT00836368

In Vitro Basophil Responsiveness to Allergen Challenge After Gamma-tocopherol Supplementation in Allergic Asthmatics

A Phase 1 study testing gamma-tocopherol in people with Allergic and Asthmatic, run by University of North Carolina, Chapel Hill at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Purpose: This is a non-masked study with a primary endpoint of in vitro basophil activation by the allergen D. farinae, comparing basophil activation before and after seven days of supplementation. Read more about this study

Who is it for?
Ages 18 to 50 years
Conditions the study is for
Allergic, Asthmatic, Allergy
What is being tested?
gamma-tocopherol
Type of treatment
Pill or oral medicine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
25 participants
Where
1 siteUnited States
Study dates
Dec 2008to Dec 2010
Phase
Phase 1
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 50 years
  • All sexes
  • No healthy volunteers
  • Adult

Who may be able to join

  • 1. Specific allergy to House Dust Mite farinae confirmed by positive immediate skin test response.
  • 2. Oxygen saturation of > 94 % at baseline 3. Blood pressure within the following parameters (Systolic between 140 - 90, Diastolic between 90-60 mm Hg) 4. Moderate or severe persistent asthma according to NHLBI definitions including history of one of the following:
  • Episodic wheezing, chest tightness or shortness of breath consistent with asthma occurring at least once a week that may affect activity
  • Asthma symptoms occurring at night or during sleep at least 1 time per week
  • measured FEV1 or FVC is <80% of predicted OR
  • Physician diagnosed moderate or severe persistent asthma which is currently treated or controlled with maintenance medication including moderate or high dose inhaled corticosteroid, or any dose of inhaled corticosteroid and a long-acting inhaled B2-agonist

Who cannot join

  • 1. Any chronic medical condition considered by the PI as a contraindication to receiving gamma-T, including significant cardiovascular disease, diabetes requiring medication, chronic renal disease, chronic thyroid disease, kidney disease or coagulation defects.
  • 2. Use of inhaled steroids, cromolyn or leukotriene inhibitors (Montelukast or Zafirlukast) which have been used for at least one month are allowed. Patients must be on a stable regimen of maintenance asthma therapy which has not changed in the past month prior to entrance into the study.
  • 3. Non-steroidal Anti-Inflammatory Drugs (NSAIDS) or aspirin (ASA) use within 48 hours of beginning the study, and inability to suspended use of these medications during the length of the study.
  • 4. Use of anticoagulants including warfarin, heparin, or clopidogrel. 5. Diagnosis of anemia or abnormal blood counts at screening. Abnormal PT or PTT values at screening (PT that is prolonged more than 1-2 sec and PTT prolonged more than 3-5 sec of normal. The normal values used will be those defined by McLendon lab.) 6. Pregnancy or nursing a baby. As this is a phase I study, the potential risk to a fetus cannot be justified.
  • 7. Children will not be included in this study as the potential risk to a growing child cannot be justified.
  • 8. Adults age 51 and older are excluded as the potential for concomitant illness in this population increases the risk for confounding the data.
  • 9. Known vagal response to venipuncture 10. Use of any tobacco product within the past 6 months 11. Hypertension, classified as a systolic blood pressure of equal to or greater than 140, and a diastolic blood pressure equal to or greater than 90.

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Center for Environmental Medicine Asthma and Lung Biology

    Chapel Hill, North Carolina, 27599

Other trials in United States

About this study

Purpose: This is a non-masked study with a primary endpoint of in vitro basophil activation by the allergen D. farinae, comparing basophil activation before and after seven days of supplementation. Secondary endpoints will include circulating antioxidant levels (tocopherols and metabolites), in vitro basophil activation to IgG anti-IgE and to N-formyl-methionyl-leucyl-phenylalanine (f-met-leu-phe), and monocyte and basophil responsiveness to in vitro endotoxin challenge.

Participants: Twenty allergic asthmatic volunteers Procedures (methods): Volunteers will be given 1200 mg of a gamma tocopherol enriched supplement, a commercially available supplement form of vitamin E. Study participants will undergo assessment of general health, lung function assessment, symptom scoring, and epicutaneous skin test to allergens at baseline and after supplementation. Blood samples will be collected at baseline and after 7 days of gamma-T treatment.

Read the detailed description

Oxidant stress plays an important role in mucosal inflammation such as seen with asthma. Previous studies have also shown that asthmatic individuals tend to have lower endogenous levels of antioxidant such as vitamins E and C, and that supplementing antioxidants can decrease exacerbations associated with ozone exposure in children. We are interested in future studies to examine the benefits of gamma-tocopherol supplementation for people with allergic asthma. This current study will determine if gamma tocopherol supplementation reduces allergic responses in vitro, providing us information that will allow us to design future masked placebo-controlled studies of this potentially important antioxidant on in vivo allergic responses.

The purpose of this study is to address the question if in vivo gamma-tocopherol supplementation at 1200 mg daily blunts allergen-specific inflammatory responses in vitro. Members of our group have previously shown that administration of 100 mg/kg of gamma tocopherol daily for four days prior to Ova challenge in sensitized allergic brown Norway rats prevented eosinophil infiltration into the airways1. In addition, this dose of gamma tocopherol blunted production of IL-4, IL-5, IL-13, IFN-gamma in the nasal airway; and PGE2, LTB4 and cysteinyl leukotrienes by the pulmonary airway. Mucous cell metaplasia was decreased as well in the gamma Tocopherol treatment group 1. In an in vivo study of gamma tocopherol performed at our center (IRB# 05-CEMALB-1407), we found that daily administration of 2 capsules of a gamma tocopherol rich preparation (each capsule containing 623 mg of gamma tocopherol, 61.1 mg of d-alpha-tocopherol, and 11.1 mg of d-beta tocopherol), was able to increase serum levels of gamma tocopherol to 18.6 + 2.6 uM after 8 days of daily administration; serum levels of alpha tocopherol were 25.2 + 2.4 uM, and delta-tocopherol were 5.1 + 1.1 uM2 . Using the data from the in vivo study, we performed basophil activation tests on dust mite allergic subjects, pretreating blood obtained from venipuncture with pharmacologic doses attained in the vivo study with gT, aT, gCEHC, and aCEHC. We found that gT, gCEHC, and aCEHC blunted basophil activation induced by the allergen D. farinae, as measured by upregulation of CD63 on the cell surface of basophils. As secondary aims, we will also examine the effect of gamma tocopherol supplementation on non-allergic stimuli that have been shown to activate basophils, such as IgG anti-IgE and N-formyl-methionyl-leucyl-phenylalanine (f-met-leu-phe), as well as in vivo allergen-specific responsiveness through epicutaneous skin testing before and after supplementation. Exploratory analyses will include assessing the effect of gamma tocopherol supplementation on monocyte and basophil responsiveness to in vitro endotoxin and lipoteichoic acid challenge.

Being tested
gamma-tocopherol
Keywords
Asthma, Asthmatic, Allergy, Allergic, Gamma-tocopherol, Vitamin, Vitamin E
Medical subject headings
Asthma, Hypersensitivity

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • gamma-tocopherolDietary supplement

    Also called Vitamin E

    oral doses 1,200 mg of gamma tocopherol (2 capsules of the gamma tocopherol enriched vitamin E preparation)

Study groups in NCT00836368
Study groupRoleWhat they receive
MaxiGammaExperimentalNot described
Receives: Dietary Supplement: gamma-tocopherol

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. We intend to examine the effect of once daily oral doses 1,200 mg of gamma tocopherol (2 capsules of the gamma tocopherol enriched vitamin E preparation) on in vitro basophil activation with D. farinae challenge.

    Measured: 7 sdays post gamma-tocopherol treatment

Secondary outcomes (1)
  1. Circulating antioxidant levels(tocopherols and metabolites), in-vitro basophil activation to IgG anti-IgE and to N-formyl-methionyl-leucyl-phenylalanine.

    Measured: 7 days post gamma-tocopherol treatment

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted4 Feb 2009 (estimated)
  2. Study startDec 2008
  3. Primary completionDec 2010
  4. Study completionDec 2010

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
25 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00836368
Sponsor's protocol ID
P01AT002620
Other IDs
P01AT002620, IRB#08-1884
Acronym
Gammaphil
Status last verified
Nov 2011
First submitted
3 Feb 2009
Last updated
7 Nov 2011
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing gamma-tocopherol in people with Allergic and Asthmatic, run by University of North Carolina, Chapel Hill at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 7 Nov 2011. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

We intend to examine the effect of once daily oral doses 1,200 mg of gamma tocopherol (2 capsules of the gamma tocopherol enriched vitamin E preparation) on in vitro basophil activation with D. farinae challenge. (time frame: 7 sdays post gamma-tocopherol treatment). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Nov 2011; AzTrials last refreshed its copy on 6 Nov 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in